Changmao Bio Releases Updated Articles of Association, Clarifies Capital Structure and Governance Framework

Bulletin Express
06/09

Changmao Biochemical Engineering Company Limited (“Changmao Bio”; 00954) has published its complete, newly adopted Articles of Association, detailing the company’s capital composition, governance architecture, shareholder rights and key operating policies.

Key Highlights

1. Capital Structure • Registered capital stands at RMB 52.97 million, represented by 529.70 million ordinary shares. • Current share mix: 0.47 % Domestic Shares, 64.85 % Non-listed Foreign Shares and 34.68 % Overseas Listed Foreign Shares. • Par value per share remains RMB 0.10. • The Articles allow for future issues of different share classes, subject to shareholder and regulatory approval.

2. Board Composition and Committees • Board size fixed at nine directors, including a minimum of three independent non-executive directors (≥ one-third of the board). • Chairperson elected by simple majority of directors for a renewable three-year term. • Mandatory establishment of Audit, Remuneration & Appraisal, Nomination and Strategy Committees; the Audit Committee must be majority independent non-executive directors and chaired by an accounting professional.

3. Supervisory Committee • Three-member body with at least one-third employee representatives and a three-year renewable term. • Empowered to examine financial affairs, monitor director and management conduct, and call extraordinary shareholder meetings when necessary.

4. Profit Allocation Policy • Profit after tax is applied in the following order: loss recovery, 10 % statutory reserve (until it reaches 50 % of registered capital), preference share dividends (if any), discretionary reserve, and ordinary dividends. • Annual dividends are payable within six months of fiscal year-end; interim dividends require shareholder authorisation and are capped at 50 % of interim distributable profit.

5. Shareholder Protections • One-share-one-vote principle applies; major corporate actions—including mergers, demergers, dissolution, capital changes and changes to the Articles—require approval by at least two-thirds of voting shares. • Detailed procedures specified for class-share meetings, proxy voting and dispute resolution through arbitration in Hong Kong or mainland China.

6. Capital Management Flexibility • The company may repurchase shares for capital reduction, merger needs or other lawful purposes, funded from distributable profits or new share proceeds. • Non-listed shares can be listed overseas subject to a special shareholder resolution and regulatory filings.

7. Disclosure & Reporting • Financial statements must comply with PRC GAAP and either IFRS or Hong Kong GAAP, with any differences disclosed; interim results released within 60 days of half-year end and full-year results within 120 days. • Dividend and other shareholder communications may be distributed electronically via the company and Hong Kong Stock Exchange websites, subject to local regulations.

The revised Articles, effective upon shareholders’ approval and regulatory filing, provide a comprehensive governance roadmap aimed at aligning Changmao Bio’s operations with both PRC regulations and Hong Kong listing requirements.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10